Petros Pharmaceuticals, Inc.
PTPI
$0.0919
-$0.0106-10.34%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -42.41% | 6.96% | -22.36% | -2.83% | 61.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -42.41% | 6.96% | -22.36% | -2.83% | 61.43% |
| Cost of Revenue | -53.02% | -45.01% | -40.35% | -28.75% | 42.54% |
| Gross Profit | -37.02% | 78.60% | -10.77% | 13.20% | 73.11% |
| SG&A Expenses | 9.38% | 4.27% | -5.74% | -24.14% | -30.90% |
| Depreciation & Amortization | -12.34% | -25.80% | -34.76% | -41.36% | -46.71% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.76% | -3.44% | -6.49% | -24.05% | -30.09% |
| Operating Income | -38.30% | 6.29% | -0.73% | 32.08% | 50.17% |
| Income Before Tax | 62.82% | 67.90% | 57.92% | 59.26% | 47.03% |
| Income Tax Expenses | -- | -- | -- | -- | -800.00% |
| Earnings from Continuing Operations | 62.79% | 67.90% | 57.92% | 59.26% | 47.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 62.79% | 67.90% | 57.92% | 59.26% | 47.08% |
| EBIT | -38.30% | 6.29% | -0.73% | 32.08% | 50.17% |
| EBITDA | -65.05% | -1.81% | -21.24% | 27.01% | 51.83% |
| EPS Basic | 30.50% | 33.79% | 23.57% | 29.58% | 49.70% |
| Normalized Basic EPS | 68.50% | 45.17% | 25.75% | 35.12% | 47.51% |
| EPS Diluted | 30.50% | 33.79% | 23.57% | 29.58% | 49.74% |
| Normalized Diluted EPS | 68.50% | 45.17% | 25.75% | 35.12% | 47.51% |
| Average Basic Shares Outstanding | 189.87% | 99.31% | 36.99% | 5.11% | 10.21% |
| Average Diluted Shares Outstanding | 189.87% | 99.31% | 36.99% | 5.11% | 10.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
